Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kamal Fadalla"'
Publikováno v:
Case Reports in Hematology, Vol 2023 (2023)
Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the BCR::ABL1 tyrosine kina
Externí odkaz:
https://doaj.org/article/45cfd3120dc54aeb8d83cad8344691e7
Autor:
Ghaleb Elyamany, Kamal Fadalla, Hatem Elghezal, Omar Alsuhaibani, Hani Osman, Abdulaziz Al-Abulaaly
Publikováno v:
Clinical Medicine Insights: Pathology, Vol 2014, Iss 7, Pp 21-27 (2014)
Externí odkaz:
https://doaj.org/article/6c798222ab00434aa847ddb370cceccb
Autor:
Eilis Nic Dhonncha, Kamal Fadalla, Blaithin Moriarty, David Gibbons, Conor D. Collins, Aurelie Fabre, Paul Collins
Publikováno v:
Journal of Dermatological Treatment, Vol 28, Iss 8, Pp 764-765 (2017)
Externí odkaz:
https://doaj.org/article/8efbf91f21a64fcd88eaedce33837557
Autor:
Ghaleb Elyamany, Mohamed Awad, Omar Alsuhaibani, Kamal Fadalla, Omer Al Sharif, Mohammad Al Shahrani, Fahad Alabbas, Abdulaziz Al-Abulaaly
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 6, Iss 1, Pp e2014038-e2014038 (2014)
The fms-like tyrosine kinase 3 (FLT3) gene is a member of the class III receptor tyrosine kinase family, mutations of FLT3 were first described in 1997 and account for the most frequent molecular mutations in acute myeloid leukemia. No data currentl
Externí odkaz:
https://doaj.org/article/291f610744c74af5af24616221843f68
Autor:
Ghaleb Elyamany, Mohammad Awad, Kamal Fadalla, Mohamed Albalawi, Mohammad Al Shahrani, Abdulaziz Al Abdulaaly
Publikováno v:
Advances in Hematology, Vol 2014 (2014)
The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. Mutations of FLT3 were first described in 1997 and account for the most freque
Externí odkaz:
https://doaj.org/article/248a411b80124fddaf3ba256be270c86
Autor:
Michael Fay, Derville O’ Shea, Anne Fortune, Liam Smyth, Su Wai Maung, Ronan Desmond, DG Connaghan, Laura McDonald, Catherine Wall, Eoghan Dunlea, Kamal Fadalla, Helen Enright, Eileen Ryan, Sarah Kelliher, Senthil Kumar, Roseann O’ Doherty
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(10)
Posttransplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplant. We identified 40 patients diagnosed with PTLD between 2009 and 2020 and analyzed their presentation, treatment strategies, and outcomes. Median age a
Autor:
Kate O'Mahony, Chandan D'Souza, Shane Toolan, Niall Swan, Joy Lewis, Joan Marie Fitzgerald, Kamal Fadalla, Daniel G Connaghan, Karen Murphy, Mark R.E. Coyne, Conor D. Collins, Mark Griffin, Liam Smyth, Gibbons David, Crotty Tom
Publikováno v:
Blood. 136:37-38
Introduction The introduction of novel therapies has significantly improved outcomes in myeloma. However, the economic burden of enhanced healthcare utilization is significant and cannot be discounted. This study sought to identify baseline character
Autor:
Kamal Fadalla, Laura McDonald
Publikováno v:
Annals of Hematology. 98:1517-1518
Autor:
Kamal Fadalla, Blaithin Moriarty, Conor D. Collins, Eilis Nic Dhonncha, Paul Collins, Aurelie Fabre, David Gibbons
Publikováno v:
Journal of Dermatological Treatment. 28:764-765
Dear Editors,In April 2014, a 52-year-old male presented with a 7-week history of an itchy erythematous facial eruption, which spread to his trunk and limbs. He had a history of hypertension treate...
Autor:
Abdulaziz Al Abdulaaly, Mohammad Awad, Mohamed Albalawi, Ghaleb Elyamany, Kamal Fadalla, Mohammad Al Shahrani
Publikováno v:
Advances in Hematology, Vol 2014 (2014)
Advances in Hematology
Advances in Hematology
The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. Mutations ofFLT3were first described in 1997 and account for the most frequent